Silu Yang

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato et al. · BMJ · 2024 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17

Zika virus infection disrupts neurovascular development and results in postnatal microcephaly with brain damage

Qiang Shao, Stephanie Herrlinger, Silu Yang et al. · Development · 2016 · 208 citations

Life Sciences, Neurobiology, Neuroscience +17

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Lin Shen, Jun Guo, Qingyuan Zhang et al. · Journal for ImmunoTherapy of Cancer · 2020 · 161 citations · Full text

Medicine, Oncology, Pharmacology +17

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Markus Moehler, Ken Kato, Hendrik‐Tobias Arkenau et al. · Journal of Clinical Oncology · 2023 · 78 citations

Medicine, Oncology, Pharmacology +17

Ubiquitin Ligase Components Cullin4 and DDB1 Are Essential for DNA Methylation in Neurospora crassa

Yuanbiao Zhao, Ye Shen, Silu Yang et al. · Journal of Biological Chemistry · 2009 · 64 citations · Full text

Life Sciences, Genetics, Molecular Biology +13